Rojkjaer Lisa 4

What Happened
Lisa Rojkjaer, Executive Vice President and Chief Medical Officer of Rigel Pharmaceuticals (RIGL), disposed of 3,758 shares on Feb 10, 2026 by surrendering them to satisfy a tax obligation (transaction code F). The shares are reported at $34.62 each, totaling approximately $130,102. This was a tax-withholding disposition tied to an equity award or option exercise, not an open-market sale.

Key Details

• Transaction date and price: Feb 10, 2026 — 3,758 shares at $34.62 each (total ~$130,102).
• Transaction type: Code F — payment of exercise price or tax liability (shares withheld/surrendered for taxes).
• Shares owned after transaction: Not specified in the provided filing.
• Filing date: Feb 12, 2026 (reported two days after the transaction), which appears timely under Form 4 reporting rules.
• No footnotes or 10b5-1 plan details were provided in the information supplied.

Context

• A code F disposition typically means shares were withheld or surrendered to cover taxes after an option exercise or RSU vesting — commonly called a "sell-to-cover" or tax-withholding transaction.
• This is routine administrative action and differs from an open-market sale; it does not necessarily indicate a change in the insider's view of the company.